Hi-Tech Receives FDA Clearance For Tropazone Lotion

Hi-Tech Pharmacal (Hi-Tech) has received clearance from the FDA to market Tropazone lotion, a prescription dermatological product which is expected to be promoted by Hi-Tech’s branded marketing subsidiary, ECR Pharmaceuticals (ECR).

Tropazone lotion is indicated for the treatment of various dermatological conditions including atopic dermatitis, allergic contact dermatitis, and radiation dermatitis. Tropazone utilises patented Lyphazome technology.

Reportedly, Lyphazome technology prolongs product activity while enhancing penetration and hydration of the skin. Tropazone is patent protected, and two additional patents are pending. Tropazone is expected to be promoted by ECR’s 55 person field force beginning February 2010.

David Seltzer, president and CEO of Hi-Tech Pharmacal, said: “We are pleased to introduce another unique prescription branded product to the market. Tropazone lotion provides physicians and their patients with an effective delivery system to treat dermatitis.”